Navigation Links
Record Breaking $327 Million Verdict Announced in Janssen Case
Date:6/3/2011

SPARTANBURG, S.C., June 3, 2011 /PRNewswire/ -- Civil penalties amounting to $327,073,700 have been announced in the groundbreaking case of State of South Carolina versus Ortho-McNeil-Janssen Pharmaceuticals and Johnson & Johnson, Inc.  Circuit Court Judge Roger Couch announced the ruling on June 3 through a written order. John B. White, Jr. and Donald C. Coggins, Jr. of Harrison, White, Smith & Coggins, P.C., a Spartanburg-based law firm, along with John Simmons of the Simmons Law Firm, a Columbia-based law firm, and Bailey Perrin Bailey, a Texas based law firm represented South Carolina in the case.

The verdict amount is based upon violations found with the drug labels and "dear doctor" letters. Regarding the drug label violations, the judge ruled that 509,499 package inserts were distributed with sample boxes, and levied $300 per violation for a total drug label awarded damages of $152,849,700. Regarding the "dear doctor" letter violations, the judge ruled that 7,184 letters were mailed and 36,372 were provided during sales calls, and levied $4000 per violation for a total "dear doctor" letter awarded damages of $174,224,000. The combination of the drug label and letter damages of $327,073,700 amounts to the highest verdict brought against Janssen for the drug Risperdal.

"The verdict handed down by the jury is just and speaks the truth," stated John B. White, Jr. one of the attorneys representing the state in the case. "The damages awarded further substantiate the level of deception Janssen used in business practices in our state."

On March 22, 2011 a jury in the Spartanburg Court of Common Pleas found that New Jersey-based Janssen willfully violated the South Carolina Unfair Trade Practices Act by engaging in unfair or deceptive acts or practices in the conduct of any trade or commerce in the "dear doctor" letter of November 10, 2003 and the drug label (package insert). This decision represents the first jury verdict that finds the defendant violated unfair trade practices since the inception of its pharmaceutical product. The "dear doctor" letter, sent to more than 7,000 doctors across South Carolina, and the package insert were found to be misleading about the safety and effectiveness of the antipsychotic drug Risperdal. Risperdal was introduced by Janssen in 1994 and by 2005, generated annual revenues in excess of $3.5 billion.

To learn more about Harrison, White, Smith and Coggins, P.C., visit www.spartanlaw.com

Contact: Sims Hammond, (864) 580-2350


'/>"/>
SOURCE Harrison, White, Smith and Coggins, P.C.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
2. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
3. Test for Life Campaign Screens Record Number of DC Residents for HIV/AIDS
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
6. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
7. Record Door-to-Balloon Time at Presbyterian Hospital of Dallas
8. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
9. Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center
10. Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology
11. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... Pa. , Sept. 5, 2017  Xyntek Inc. has announced another milestone ... a new Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 ... ... of customer engagements regionally. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that ... clinical and commercial support services market) has entered into an agreement on September ... , The PGSD is the first private Dental School to launch an ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic ... National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, ... when Athletic Trainers are acknowledged by their peers with accolades and highly prestigious ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
(Date:9/20/2017)... ... ... Health & Safety Institute (HSI) is offering discounted pricing on its Summit ... now until November 30, 2017 to assist with the clean-up efforts from hurricanes Harvey ... and government agencies – whether or not they will be directly involved in the ...
(Date:9/20/2017)... ... September 20, 2017 , ... “RECYCLED Ezekiel's Plan for Freedom ... Freedom from ADDICTION” is the creation of published author, Bill Miller. Bill ... homeless services, including more than a decade of addiction to prescription drugs. ...
Breaking Medicine News(10 mins):